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Background. Transcobalamin II is a serum protein that trans-
ports vitamin B12 from the intestine to the tissues. This complex,
holo-transcobalamin II, may reflect vitamin B12 availability in
the body. Conflicting data exist with regard to the effect of a
polymorphism in the gene coding for transcobalamin II, TCN2
776CG, on transcobalamin II levels in the general population,
which in turn may affect holo-transcobalamin II, vitamin B12,
as well as total homocysteine (tHcy) plasma levels. The effect
of TCN2 776CG on vitamin B12 cellular availability in dialysis
patients is unknown.
Methods. We examined the effect of TCN2 776CG on holo-
transcobalamin II, vitamin B12, and tHcy plasma concentrations
in 120 dialysis patients.
Results. Holo-transcobalamin II levels were normal or su-
pranormal in all patients and showed a linear association with
albumin (r 0.205, P 0.025) and with vitamin B12 (r 0.778,
P  0.001), but not with age, creatinine, body mass index, tHcy,
ln-tHcy, vitamin B6, plasma folate, and red blood cell folate
concentration. TCN2 776CG showed no effect on holo-trans-
cobalamin II, vitamin B12, and tHcy concentration [one-way
analysis of variance (ANOVA), post-hoc Scheffe test]. Multiple
linear regression analyses showed that albumin and B12 are
independently associated with holo-transcobalamin II, whereas
TCN2 776CG and MTHFR 677CT had no effect. Indepen-
dent predictors of ln-tHcy included creatinine, red blood cell
folate, and the MTHFR 677TT genotype. There was also an effect
of the TCN2 776CC genotype on ln-tHcy levels in this multivariate
analysis, however, that deserves cautious interpretation be-
cause there was no effect of TCN2 genotypes by ANOVA and
Scheffe test [median ln-tHcy concentrations according to TCN2
genotypes (mol/L): CC, 3.22; CG, 3.30; GG, 3.23].
Conclusion. TCN2 776CG does not influence holo-trans-
cobalamin II or vitamin B12 levels, and has no major effect on
tHcy concentrations of end-stage renal disease patients.
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Hyperhomocysteinemia is an established risk factor
for cardiovascular disease [1]. In the cell, 5-methyltet-
rahydrofolate and vitamin B12 (cobalamin) are required
for remethylation of homocysteine (Hcy) to methionine,
which is mediated by methionine synthase and methio-
nine synthase reductase. Therefore, intracellular avail-
ability of vitamin B12 influences total Hcy (tHcy) plasma
concentrations.
Three proteins are involved in vitamin B12 transport
in the body. In the stomach, vitamin B12 binds to intrinsic
factor, which is essential for the intestinal vitamin up-
take. In the plasma, 20% to 30% of vitamin B12 is bound
to transcobalamin II (TC II). The complex of vitamin
B12 bound to transcobalamin II is termed holo-transcoba-
lamin II (holo-TC II). The cellular supply with vitamin B12
is, therefore, related to the concentration of holo-TC II in
the circulation. Consequently, low holo-TC II concentra-
tions may be an early indicator of vitamin B12 deficiency.
The remaining 70% to 80% of vitamin B12 is bound to
haptocorrin, the role of which is not completely under-
stood, but which may act as a storage protein. Previously,
TC II was suggested to be an acute-phase protein because
its levels may increase during certain disorders (e.g., prolif-
erative histiocytosis) [2]. However, more recent literature
tends to take the opposite view, as studies have found
no correlation between levels of TC II and C-reactive
protein [3]. Holo-transcobalamin II has never been pro-
moted as an acute-phase protein [4]. Nevertheless, pa-
tients with a myocardial infarction showed elevated levels
of holo-TC, which were assumed to be related to major
tissue injury (Lars Orning, personal communication, 2003).
A polymorphism (TCN2 776CG; P259R) in the TC II
gene (TCN2) has an effect on the concentration of blood
TC II [5]. In healthy Caucasian individuals with the TCN2
CC genotype, TC II concentrations were higher com-
pared to heterozygotes or individuals homozygous for
the G allele. Furthermore, heterozygotes showed higher
tHcy plasma concentrations compared to both homozy-
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gous genotypes [5], suggesting that TCN2 776CG inter-
feres with vitamin B12 cellular delivery and Hcy metabo-
lism. By contrast, others observed no major effect of
TCN2 776CG on plasma tHcy and plasma vitamin B12
concentration, as well as a decrease of holo-TC II con-
centrations, raising the question of the impact of TCN2
776CG on vitamin B12 cellular delivery and tHcy con-
centrations [6–8]. Even lower tHcy concentrations have
been observed in individuals in the upper quartile of
vitamin B12 levels with the TCN2 776GG genotype [9].
Hyperhomocysteinemia is present in the majority of
dialysis patients and is influenced by vitamin deficiencies
and genetic factors [10, 11]. The effect of TCN2 776CG
on vitamin B12 cellular availability in patients with renal
failure is unknown. We therefore examined the impact
of TCN2 776CG on tHcy, vitamin B12, and holo-TC II
concentrations among chronic dialysis patients.
METHODS
Study design
This cross-sectional study was conducted in 120 end-
stage renal disease patients who participated in two stud-
ies related to hyperhomocysteinemia in renal disease
[12, 13]. None of the peritoneal dialysis patients received
routine folic acid or B vitamin supplementation. The
hemodialysis patients received a multivitamin containing
0.16 mg of folic acid and 10 mg of vitamin B6, besides
other vitamins, but not vitamin B12 (Dreisavit-Filmtablet-
ten, GRY-Pharma GmbH, Kirchzarten, Germany), and
which has no effect on tHcy plasma levels [14]. The
ethical review board at the University of Vienna ap-
proved the study. All patients gave written informed
consent according to the Declaration of Helsinki.
Biochemical methods
Blood was drawn after an overnight fast in peritoneal
dialysis patients and pre-dialysis (after the two-day inter-
val) in hemodialysis patients, anticoagulated with ethyl-
enediaminetetraacetic acid (EDTA), immediately placed
on crushed ice, and protected from light.
Blood aliquots for extraction of DNA were snap fro-
zen at 70C. Blood aliquots for determination of red
blood cell folate concentration were hemolyzed with
0.2% ascorbic acid (1:21) for two hours and frozen at
70C. Red blood cell folate was determined using a
radioassay (SimulTRAC-SNB, ICN Pharmaceuticals,
Inc., Costa Mesa, CA, USA) according to the instruc-
tions of the manufacturer [red blood cell folate (nmol/L
of packed red blood cells) (hemolysate folate concentra-
tion)  21/(hematocrit in decimal notation); normal:
272 nmol/L]. The remaining EDTA-anticoagulated
blood samples were centrifuged within 30 minutes at
2000g at 4C (20 minutes), and plasma aliquots for deter-
mination of tHcy, folate, vitamin B6, vitamin B12, and
holo-TC II were snap-frozen and stored at 70C.
Holo-transcobalamin II plasma levels (reference range,
30 to 160 pmol/L) were measured by a radioimmuno-
assay (HoloTC RIA; Axis-Shield, Oslo, Norway). The tHcy
plasma concentration was determined by a fluorescence
polarization immunoassay (IMx analyzer; Abbott Labo-
ratories, Abbott Park, IL, USA). Hyperhomocysteinemia
was defined as a tHcy plasma level above 15mol/L [15].
Folate (normal, 3.4 nmol/L) and vitamin B12 (normal,
118 pmol/L) plasma level were measured with a ra-
dioassay (Simul TRAC-SNB; ICN Pharmaceuticals, Inc.,
Costa Mesa, CA, USA). Vitamin B6 plasma level (nor-
mal,20 nmol/L) was determined with a radioenzymatic
assay (Bu¨hlmann Laboratories AG, Allschwil, Switzer-
land).
Identification of the TCN2 776CG polymorphism
was performed using an amplification refractory muta-
tion system [5]. Identification of the 677CT transition
in MTHFR was performed as previously described [16].
Statistical analyses
Continuous data are given as mean  standard devia-
tion or as median and quartiles. Categorical data are
given as absolute counts and percentages. Because tHcy
concentration was positively skewed, we used logarith-
mic transformation to normalize the distribution.
We analyzed linear associations using Pearson’s corre-
lation. The effect of the different genotypes of TCN2
776CG or MTHFR 677CT on vitamin B12, holo-TC
II, and tHcy plasma levels was assessed in a one-way
analysis of variance (ANOVA) and post-hoc Scheffe test.
Multiple linear regression analyses with all variables
that showed a linear association (P  0.1) with ln-tHcy
or holo-TC II including polymorphisms (genotypes coded
as dummy variables) with a significant effect in the one-
way ANOVA models were established to assess the inde-
pendent effects on ln-tHcy or holo-TC II.
In a second set of multiple linear regression analyses,
both polymorphisms were included in models examining
the effects on ln-tHcy and on holo-TC II plasma concen-
trations.
The third set of analyses included interaction terms of
the genotypes with an effect on ln-tHcy or holo-TC II.
All analyses were performed using SPSS (Windows
version 10.0.7; Macintosh version 10.0.8; SPSS, Inc., Chi-
cago, IL, USA). To detect an increase in tHcy of 8mol/L
from 25 to 33 mol/L in homozygous versus heterozy-
gous patients with a type 2 error of 0.05 and a power of
80%, 25 subjects were needed in each group.
RESULTS
Patients and genotypes
The characteristics of all patients are indicated in Ta-
ble 1. The allele frequency of TCN2 776G in our study
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Table 1. Patient characteristics
Gender female/male 53/67
Age years 55.415.7
Body mass index kg/m2 23.73.8
Duration of dialysis treatment years 2.22.0
Peritoneal dialysis/hemodialysis N 54/66
was 0.4, which is comparable to the frequency of 0.42
and 0.47 observed by others [5–9]. Among our patients,
18.3% were homozygous for the TCN2 775G allele and
42.5% were heterozygotes.
Vitamin levels and tHcy plasma concentrations
The plasma levels of tHcy, holo-TC II, vitamin B12,
folates and vitamin B6, and of other biochemical vari-
ables are indicated in Table 2 and 3 according to TCN2
and MTHFR genotypes. Low plasma levels (less then
30 pmol/L) of holo-TC II were observed in none of our
patients, plasma levels were above 160 pmol/L in 38
patients. Hyperhomocysteinemia was present in 112 pa-
tients. Vitamin B12 levels of less than 118 nmol/L were
measured in 7 patients. Folate plasma levels, as well as
red blood cell folate concentrations, were not decreased
in any patient.
There was a linear association of holo-TC II with albu-
min (r  0.205, P  0.025) and with vitamin B12 (r 
0.778, P  0.001), but not with creatinine (P  0.058),
age, body mass index (BMI), ln-tHcy, vitamin B6, plasma
folate, and red blood cell folate concentration.
We observed a linear association of ln-tHcy with creat-
inine (r  0.474, P  0.001), albumin (r  0.284, P 
0.002), serum folate (r  0.338, P  0.001), and red
blood cell folate (r  0.472, P  0.001). There was no
effect of age (P  0.051), vitamin B12 (P  0.087), BMI,
vitamin B6, and holo-TC II.
There was no effect of TCN2 776CG on plasma
levels of vitamin B12, holo-TC II, and plasma tHcy/ln-tHcy
concentrations (one-way ANOVA, post-hoc Scheffe test)
(Table 2). The MTHFR 677CT genotypes showed a
significant effect on plasma ln-tHcy levels, but not on
holo-TC II or vitamin B12 levels (one-way ANOVA, post-
hoc Scheffe test) (Table 3).
Independent effects of TCN2 and MTHFR genotypes
on holo-TC II and ln-tHcy concentrations
Multiple linear regression analysis including relevant
variables (creatinine, albumin, vitamin B12) showed an
independent association of albumin and vitamin B12 with
holo-TC II levels (Table 4, Model 1). Including MTHFR
(Table 4, Model 2), TCN2 (Table 4, Model 3), or both
polymorphisms (Table 4, Model 4) in the analysis revealed
no effect on holo-TC II concentrations. There was no
interaction of genotypes that showed an effect on ln-tHcy
(TCN2 776CC x MTHFR 677TT) (Table 4, Model 5).
We found a significant independent effect of creati-
nine, red blood cell folate, and MTHFR 677TT genotype
on ln-tHcy plasma concentrations (Table 5, Model 1),
whereas age, albumin, vitamin B12, serum folate, and
MTHFR 677CC, or CT genotype showed no effect by
multiple linear regression analysis. Including TCN2 geno-
types in this analysis disclosed an independent effect of
TCN2 776CC genotype on ln-tHcy concentrations (Table
5, Model 2). This effect remained when MTHFR and
TCN2 were both included in the analysis (Table 5, Model
3), but disappeared following the inclusion of an interac-
tion term TCN2 776CC  MTHFR 677TT (Table 5,
Model 4).
DISCUSSION
None of the end-stage renal disease patients included
in this analysis showed decreased holo-TC II plasma
levels, which is in line with previous observations in renal
failure patients [17]. There was a linear association of
holo-TC II with albumin and vitamin B12, but not with
age or ln-tHcy plasma concentration. Our study shows
that the 776CG polymorphism of TCN2 has no major
effect on holo-TC II, vitamin B12 levels, and ln-tHcy
plasma concentrations. There was also no effect of
MTHFR 677CT on holo-TC II or vitamin B12 levels.
By linear multiple regression analysis, however, TCN2
showed a minor independent effect on ln-tHcy plasma
concentrations that was probably due to somewhat lower
ln-tHcy plasma concentrations in the TCN2 776CC geno-
type compared to CG/GG genotypes (Table 2).
The lack of effect of the TCN2 776CG polymor-
phism on holo-TC II levels in our study is in contrast to
two studies reporting a holo-TC II–decreasing effect of
TCN2 776CG in subjects without renal disease [7, 18].
For determination of holo-TC II plasma concentrations
we have used a commercially available radioimmuno-
assay. Because different methods have been used for de-
termination of holo-TC II in various studies, it cannot
be excluded that the observed discrepancies are due to
different test systems. Alternatively, the decreasing ef-
fect of TCN2 776CG on holo-TC II is not present in
renal failure. Interestingly, in one of the studies reporting
a holo-TC II–decreasing effect of TCN2 776CG, this
observation was not associated with an increase of tHcy
concentrations, although methylmalonic acid concentra-
tions were significantly elevated [7]. Measurement of
methylmalonic acid levels represents a tool to diagnose
vitamin B12 deficiency [19]. We have not measured meth-
ylmalonic acid levels because methylmalonic acid accu-
mulates in renal failure patients [20, 21], but it may be
useful for monitoring of vitamin B12 supplementation in
such patients [22].
The lack of effect of TCN2 776CG on vitamin B12
concentration is in line with all but one study [6–8],
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Table 2. Patient characteristics according to TCN2 776CG genotype
TCN2 776CG
CC CG GG
Dialysis patients N 47 51 22
Plasma holo-TC II pmol/La 130 (86.7–180) 117 (89–163) 143 (103–150)
Plasma vitamin B12 pmol/La 248 (172–357) 252 (186–321) 266 (189–393)
Plasma tHcy lmol/La 25 (20.9–29.5) 27.2 (22.8–33.0) 25.3 (17.8–37.5)
Plasma ln-tHcy lmol/La 3.22 (3.04–3.38) 3.30 (3.13–3.49) 3.23 (2.88–3.62)
RBC folate nmol/L 1346 (960–1731) 1180 (873–1433) 1280 (1036–1501)
Plasma folate nmol/L 17 (11.9–21.9) 16 (11.8–21.3) 18.6 (13.4–21)
Plasma vitamin B6 nmol/L 44.2 (17.7–71.8) 34.3 (17.4–104) 26.5 (9.3–58.4)
Albumin g/dL 40.8 (35.3–43.7) 39 (36.3–44.4) 35.1 (32.5–40.2)
Creatinine mg/dL 8.6 (7.2–10.8) 8.1 (6.7–9.7) 7.4 (6.4–9.1)
Hemoglobin g/dL 11.6 (10.7–12.4) 12 (11.3–12.9) 11.3 (10.2–12.1)
RBC is red blood cells. Medians, percentiles 25 and 75 are shown in parentheses.
a No effect of genotype by one-way analysis of variance; no effect of genotypes by post-hoc Scheffe test
Table 3. Patient characteristics according to MTHFR 677CT genotype
MTHFR 677CT
CC CT TT
Dialysis patients N 49 56 15
Plasma holo-TC II pmol/La 143 (98–185) 117 (84–163) 125 (72.5–142)
Plasma vitamin B12 pmol/La 276 (199–405) 234 (177–343) 195 (150–259)
Plasma tHcy lmol/Lb 24.7 (19.2–27.5) 27.1 (22.5–33.0) 31.9 (24.2–62.7)
Plasma ln-tHcy lmol/Lc 3.21 (2.96–3.31) 3.30 (3.11–3.49) 3.46 (3.19–4.11)
RBC folate nmol/L 1288 (966–1666) 1154 (938–1500) 1343 (713–1926)
Plasma folate nmol/L 17.1 (13.3–22.2) 16.0 (11.4–20.3) 15.5 (11.9–21.8)
Vitamin B6 30.0 (16.8–101) 33.2 (13.2–82.8) 47.1 (28.0–60.5)
Albumin g/dL 38.0 (33.8–43.7) 38.6 (35.1–43.4) 41.7 (38.6–44.9)
Creatinine mg/dL 8.1 (6.7–9.4) 8.5 (6.6–10.1) 8.0 (6.7–11.3)
Hemoglobin g/dL 11.5 (10.2–12.2) 11.9 (11.1–12.6) 12.7 (11.1–13.3)
RBC is red blood cell. Medians, percentiles 25 and 75 are shown in parentheses.
a No effect of genotype by one-way analysis of variance (ANOVA); no effect of genotype by post-hoc Scheffe test
b P  0.001 by ANOVA; TT vs. CC P  0.002 by post-hoc Scheffe test
c P  0.001 by ANOVA; TT vs. CC P  0.001, CT vs. CC P  0.032 by post-hoc Scheffe test
Table 4. Independent predictors of holo-TC II plasma concentrations (multiple linear regression analyses)
Model
1 2 3 4 5
	 P 	 P 	 P 	 P 	 P
Vitamin B12 0.789 0.001 0.784 0.001 0.790 0.001 0.786 0.001 0.787 0.001
Creatinine 0.085 0.137 0.087 0.131 0.082 0.153 0.084 0.148 0.102 0.086
Albumin 0.219 0.001 0.222 0.001 0.226 0.001 0.227 0.001 0.218 0.001
MTHFR 677CC —a —a 0.043 0.451 —a —a b b 0.040 0.481
MTHFR 677CT —a —a b b —a —a 0.038 0.514 b b
MTHFR 677TT —a —a 0.003 0.953 —a —a 0.021 0.729 0.101 0.256
TCN2 776CC —a —a —a —a 0.054 0.349 0.051 0.385 0.252 0.103
TCN2 776CG —a —a —a —a b b b b b b
TCN2 776GG —a —a —a —a 0.037 0.534 0.032 0.596 0.023 0.701
677TT 776CC —a —a —a —a —a —a —a —a 0.240 0.159
a Variable not included in the model; b Variable excluded by regression procedure
supporting the concept that this mutation does not influ-
ence vitamin B12 cellular delivery. Serum vitamin B12
tends to run spuriously high in some patients with renal
failure, and low in others, often not reflecting vitamin
B12 status well. Even holo-TC II tends to run high in
renal failure [17]. In this context, the kidney actively
clears TC II [23], and perhaps even synthesizes and re-
leases some holo-TC II [24]. Indeed, the holo-TC II
results of the present study consist of many elevated
values, whereas none of the patients presented with lev-
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Table 5. Independent predictors of ln-tHcy plasma concentrations (multiple linear regression analyses)
Model
1 2 3 4
	 P 	 P 	 P 	 P
Vitamin B12 0.113 0.116 0.165 0.024 0.123 0.084 0.123 0.085
Creatinine 0.338 0.001 0.339 0.001 0.348 0.001 0.343 0.001
Albumin 0.093 0.236 0.139 0.086 0.093 0.236 0.099 0.213
Age 0.017 0.830 0.003 0.969 0.007 0.925 0.022 0.787
Plasma folate 0.037 0.707 0.085 0.393 0.041 0.670 0.047 0.626
Red blood cell folate 0.331 0.001 0.315 0.003 0.325 0.001 0.316 0.002
MTHFR 677CC 0.144 0.057 —a —a 0.135 0.074 0.137 0.070
MTHFR 677CT b b —a —a b b b b
MTHFR 677TT 0.173 0.025 —a —a 0.172 0.024 0.106 0.367
TCN2 776CC —a —a 0.179 0.023 0.160 0.036 0.295 0.153
TCN2 776CG —a —a b b b b b b
TCN2 776GG —a —a 0.052 0.525 0.020 0.799 0.016 0.838
677TT  776CC —a —a —a —a —a —a 0.162 0.479
aVariable not included in the model; bvariable excluded by regression procedure
els below the reference range. By crude calculation using
the means, the percentage of the total vitamin B12 that
is bound to transcobalamin is around 50%. This is in
contrast to the literature, which says that this percentage
is usually around 20% to 30%. This observation suggests
that renal disease and/or dialysis affects total B12 and/or
holo-TC II levels in a way that has not been previously
recognized, and thus may potentially confound the results
of this study. Furthermore, there also may be a relation
to an impairment of cellular uptake of holo-TC II in renal
failure (W. Herrmann and R. Obeid, Hamburg, Germany,
personal communication, 2003).
There was no effect of TCN2 776CG on plasma ln-
tHcy concentrations in our study of dialysis patients by
one-way ANOVA (Table 2). By multiple linear regres-
sion analysis, red blood cell folate, creatinine, and the
MTHFR 6777TT genotype were independent predictors
of ln-tHcy concentrations. Inclusion of the TCN2 geno-
types in the multivariate analysis showed an independent
effect of the CC genotype that was probably due to some-
what lower ln-tHcy levels in TCN2 776CC genotype pa-
tients compared to CG/GG genotypes. The interpreta-
tion of the discrepancies of univariate and multivariate
analyses, with regard to the effect of TCN2 on ln-tHcy
levels in this study, deserves some critical appraisal. First,
the effect in the multivariate analysis may have occurred
by chance. Second, a larger study population would prob-
ably clearly disclose an effect of TCN2 776CC genotype
in renal failure patients. There is also a hint from the
literature that the effect of TCN2 776CG on tHcy may
be restricted to individuals of younger age [25].
Together, our finding of a slight effect of TCN2 on ln-
tHcy by multivariate analysis is in contrast to data of
healthy elderly individuals and dementia patients [6, 7],
but compares well with results obtained in studies of
healthy individuals [5, 8, 9], vascular disease patients [9],
and mothers of children with neural tube defects [8], re-
porting a weak tHcy elevating effect of TCN2 776CG.
These divergent observations could be due to investigation
of different study populations showing a divergent age,
genetic background, and vitamin status influencing tHcy
levels.
Finally, there was a tendency for different vitamin B6
plasma levels among the three TCN2 genotype groups
in our study, however, which was not significant by one-
way ANOVA and may be related to the multivitamin
that contained 10 mg of vitamin B6 and was prescribed
to hemodialysis patients.
CONCLUSION
TCN2 776CG does not predict holo-TC II or vitamin
B12 plasma concentrations and is no major additional
determinant of hyperhomocysteinemia of end-stage re-
nal disease patients.
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